Without the COVID-19 pandemic, projected values of biopharma nonprofit collaborations and grants would be 72% and 30% below last year’s levels, although it is impossible to know what deals may have come to fruition in a world absent of the disruptive SARS-CoV-2 virus.
PERTH, Australia – Sydney-based Recce Pharmaceuticals Ltd. completed a placement of AU$27.95 million (US$19.69 million) to advance its synthetic anti-infective pipeline to address antibiotic-resistant superbugs and emerging viral pathogens.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adial, Alexion, Blueprint, Brickell, Cardiol, Daiichi, Eisai, Galapagos, Gilead, Kaken, Neurophth, Olix, Oncoheroes, Rakuten, Remegen, Spirovant, Vertex, Xiangxue.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abcellera, Amarna, Clover, Dynavax, Endo, Fulcrum, Grand River Aseptic, GSK, IGM, Immunoprecise, J&J, Janone, Lambdavision, Litevax, Molecular Partners, Novavax, Par, Rockwell, Valo.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Apeiron, Beyondspring, BMS, Genfit, Hansa, Marinus, Menarini, Novavax, Radius Rhizen, Uniqure.
Ionpath Inc., a developer of high-definition spatial proteomics, scored $18 million in a series B funding round led by Samsara Biocapital. The round also included global mass spectrometry leader Bruker Corp. as a new investor. Menlo Park, Calif.-based Ionpath plans to use the investment for continued development and deployment of the company’s Multiplexed Ion Beam Imaging (MIBI) technology, which provides quantitative protein imaging at a subcellular level.
As Johnson & Johnson (J&J) made public the launch of a phase III trial with its COVID-19 vaccine, officials from the company and others at the virtual Biopharm America meeting discussed modes of innovation in the pandemic era.
Keeping you up to date on recent developments in diagnostics, including: Distinguishing metastatic SLNs in breast cancer; MRS method reveals insights into Alzheimer’s disease; SARS-CoV-2 multiplex assay allows 3x as many patients per run.
RSS
